Spondyloarthritis & psoriatic arthritis
The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials
Authors' conclusion
This systematic review identified 18 and 15 molecules in clinical development for axSpA and PsA, respectively, which suggests a strengthening of the therapeutic arsenal in the coming years.
Study context
- Population
- DMARDs for spondyloarthritis (SpA) (axial SpA (axSpA) and psoriatic arthritis (PsA)) already marketed, in clinical development or withdrawn
- Outcome
- DMARDs in development for axSpA and PsA
Methodological detailssearch of 17 national and international clinical trial databases, February 2023
- Search of 17 national and international clinical trial databases
- February 2023
Pooled result
As reported in the abstract
- axSpA: DMARDs identified
- 44
- axSpA: csDMARDs
- 6
- axSpA: bDMARDs
- 27
- axSpA: tsDMARDs
- 11
- axSpA: b+tsDMARDs in current development
- 18
- axSpA: trials in development reaching phase I
- 1
- axSpA: trials in development reaching phase II
- 10
- axSpA: trials in development reaching phase III
- 7
- axSpA: IL-17 inhibitors in development
- 10
- axSpA: JAKi in development
- 2
- axSpA: GM-CSF inhibitors in development
- 2
- axSpA: other mode of action
- 4
- PsA: DMARDs identified
- 44
- PsA: csDMARDs
- 5
- PsA: bDMARDs
- 27
- PsA: tsDMARDs
- 12
- PsA: molecules in current development
- 15
- PsA: trials in development reaching phase II
- 8
- PsA: trials in development reaching phase III
- 7
- PsA: JAKi in development
- 6
- PsA: IL-17 inhibitors in development
- 6
- PsA: IL-23 inhibitor in development
- 1
- PsA: other mode of action
- 2
Original publication
The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials. RMD Open. Published 28 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →